• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ELISA-R:一种基于 R 的 ELISA 数据分析稳健方法。

ELISA-R: an R-based method for robust ELISA data analysis.

机构信息

Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.

Mycobacterial Research Laboratories, Colorado State University, Fort Collins, CO, United States.

出版信息

Front Immunol. 2024 Oct 2;15:1427526. doi: 10.3389/fimmu.2024.1427526. eCollection 2024.

DOI:10.3389/fimmu.2024.1427526
PMID:39416778
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11479990/
Abstract

Enzyme-linked immunosorbent assay (ELISA) is a technique to detect the presence of an antigen or antibody in a sample. ELISA is a simple and cost-effective method that has been used for evaluating vaccine efficacy by detecting the presence of antibodies against viral/bacterial antigens and diagnosis of disease stages. Traditional ELISA data analysis utilizes a standard curve of known analyte, and the concentration of the unknown sample is determined by comparing its observed optical density against the standard curve. However, in the case of vaccine research for complicated bacteria such as (Mtb), there is no prior information regarding the antigen against which high-affinity antibodies are generated and therefore plotting a standard curve is not feasible. Consequently, the analysis of ELISA data in this instance is based on a comparison between vaccinated and unvaccinated groups. However, to the best of our knowledge, no robust data analysis method exists for "non-standard curve" ELISA. In this paper, we provide a straightforward R-based ELISA data analysis method with open access that incorporates end-point titer determination and curve-fitting models. Our modified method allows for direct measurement data input from the instrument, cleaning and arranging the dataset in the required format, and preparing the final report with calculations while leaving the raw data file unchanged. As an illustration of our method, we provide an example from our published data in which we successfully used our method to compare anti-Mtb antibodies in vaccinated vs non-vaccinated mice.

摘要

酶联免疫吸附测定(ELISA)是一种用于检测样品中抗原或抗体存在的技术。ELISA 是一种简单且具有成本效益的方法,已被用于通过检测针对病毒/细菌抗原的抗体存在来评估疫苗效力,并诊断疾病阶段。传统的 ELISA 数据分析利用已知分析物的标准曲线,通过将未知样品的观察光密度与标准曲线进行比较来确定其浓度。然而,在针对复杂细菌(如 Mtb)的疫苗研究中,对于产生高亲和力抗体的抗原没有先验信息,因此绘制标准曲线是不可行的。因此,在这种情况下,ELISA 数据的分析是基于接种组和未接种组之间的比较。然而,据我们所知,对于“非标准曲线”ELISA,还没有可靠的数据分析方法。在本文中,我们提供了一种简单的基于 R 的 ELISA 数据分析方法,具有开放访问权限,其中包括终点滴度测定和曲线拟合模型。我们的改进方法允许直接从仪器输入测量数据,清洁和整理所需格式的数据,并准备带有计算的最终报告,而原始数据文件保持不变。作为我们方法的说明,我们提供了一个来自我们已发表数据的示例,其中我们成功地使用我们的方法比较了接种组和未接种组小鼠中的抗 Mtb 抗体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/90d001646ca3/fimmu-15-1427526-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/284770a67076/fimmu-15-1427526-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/7b91086bf44e/fimmu-15-1427526-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/992cbbef9477/fimmu-15-1427526-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/6c741f23f3f4/fimmu-15-1427526-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/90d001646ca3/fimmu-15-1427526-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/284770a67076/fimmu-15-1427526-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/7b91086bf44e/fimmu-15-1427526-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/992cbbef9477/fimmu-15-1427526-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/6c741f23f3f4/fimmu-15-1427526-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/787b/11479990/90d001646ca3/fimmu-15-1427526-g005.jpg

相似文献

1
ELISA-R: an R-based method for robust ELISA data analysis.ELISA-R:一种基于 R 的 ELISA 数据分析稳健方法。
Front Immunol. 2024 Oct 2;15:1427526. doi: 10.3389/fimmu.2024.1427526. eCollection 2024.
2
Evaluation of an enzyme-linked immunosorbent assay (ELISA) using an IgG antibody to Mycobacterium tuberculosis antigen 5 in the diagnosis of active tuberculosis in children.使用针对结核分枝杆菌抗原5的IgG抗体的酶联免疫吸附测定(ELISA)在儿童活动性结核病诊断中的评估。
Am Rev Respir Dis. 1989 Mar;139(3):748-51. doi: 10.1164/ajrccm/139.3.748.
3
[Determination of anti-mycobacteria antibody titers by ELISA for the early diagnosis of tuberculosis].[酶联免疫吸附测定法检测抗分枝杆菌抗体滴度用于结核病的早期诊断]
Kekkaku. 1990 Aug;65(8):545-58.
4
[Tuberculosis serodiagnosis, ELISA (enzyme-linked immunosorbent assay) and different mycobacterial antigens].[结核病血清学诊断、酶联免疫吸附测定(ELISA)及不同分枝杆菌抗原]
Mikrobiyol Bul. 1990 Jul;24(3):198-204.
5
Circulating immune complexes in human tuberculosis sera: demonstration of specific antibodies against Mycobacterium tuberculosis glycolipid (DAT, PGLTb1, LOS) antigens in isolated circulating immune complexes.人类结核病血清中的循环免疫复合物:在分离出的循环免疫复合物中证实存在针对结核分枝杆菌糖脂(DAT、PGLTb1、LOS)抗原的特异性抗体。
Eur J Clin Invest. 1997 Feb;27(2):128-34. doi: 10.1046/j.1365-2362.1997.800626.x.
6
Dynamic evolution and immunoreactivity of aptamers binding to polyclonal antibodies against MPT64 antigen of Mycobacterium tuberculosis.与结核分枝杆菌MPT64抗原多克隆抗体结合的适配体的动态进化及免疫反应性
Eur J Clin Microbiol Infect Dis. 2014 Jul;33(7):1199-209. doi: 10.1007/s10096-014-2056-4. Epub 2014 Feb 7.
7
AhpC, AhpD, and a secreted 14-kilodalton antigen from Mycobacterium avium subsp. paratuberculosis distinguish between paratuberculosis and bovine tuberculosis in an enzyme-linked immunosorbent assay.在酶联免疫吸附测定中,鸟分枝杆菌副结核亚种的AhpC、AhpD和一种分泌型14千道尔顿抗原可区分副结核病和牛结核病。
Clin Diagn Lab Immunol. 2001 Jul;8(4):797-801. doi: 10.1128/CDLI.08.4.797-801.2001.
8
Diverse humoral immune responses and changes in IgG antibody levels against mycobacterial lipid antigens in active tuberculosis.活动性肺结核中针对分枝杆菌脂质抗原的多种体液免疫反应及IgG抗体水平变化
Microbiology (Reading). 2005 Jun;151(Pt 6):2065-2074. doi: 10.1099/mic.0.27790-0.
9
[Comparative analysis of two mycobacterium tuberculosis antigens and two methodological approaches to determining serum antimycobacterial antibodies].[两种结核分枝杆菌抗原及两种测定血清抗分枝杆菌抗体方法的比较分析]
Probl Tuberk. 1998(2):27-30.
10
A multi-antigen print immunoassay for the development of serological diagnosis of infectious diseases.一种用于传染病血清学诊断发展的多抗原印迹免疫测定法。
J Immunol Methods. 2000 Aug 28;242(1-2):91-100. doi: 10.1016/s0022-1759(00)00241-6.

本文引用的文献

1
Development and validity assessment of ELISA test with recombinant chimeric protein of SARS-CoV-2.基于 SARS-CoV-2 重组嵌合蛋白的 ELISA 检测方法的建立及其有效性评估。
J Immunol Methods. 2023 Aug;519:113489. doi: 10.1016/j.jim.2023.113489. Epub 2023 May 11.
2
Mucosal exposure to non-tuberculous mycobacteria elicits B cell-mediated immunity against pulmonary tuberculosis.黏膜接触非结核分枝杆菌会引发针对肺结核的 B 细胞介导免疫。
Cell Rep. 2022 Dec 13;41(11):111783. doi: 10.1016/j.celrep.2022.111783.
3
ELISA Test Based on the Phenolic Glycolipid-I (PGL-I) of : A Reality of a Laboratory from a Non-Endemic Country.
基于酚糖脂-I(PGL-I)的酶联免疫吸附测定(ELISA)试验:一个非流行国家实验室的实际情况
Pathogens. 2022 Aug 9;11(8):894. doi: 10.3390/pathogens11080894.
4
The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group.抗体在结核病诊断、预防和治疗中的作用:ESGMYC 研究组的综述。
Eur Respir Rev. 2022 Mar 9;31(163). doi: 10.1183/16000617.0218-2021. Print 2022 Mar 31.
5
Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants.接种疫苗无论是在感染 SARS-CoV-2 之前还是之后,都会引发强烈的体液免疫反应和能够有效中和变异株的抗体。
Sci Immunol. 2022 Feb 18;7(68):eabn8014. doi: 10.1126/sciimmunol.abn8014.
6
A novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma.一种新型竞争 ELISA 可用于快速定量恢复期血浆中的 SARS-CoV-2 中和抗体。
Transfusion. 2021 Oct;61(10):2981-2990. doi: 10.1111/trf.16652. Epub 2021 Sep 9.
7
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.人类接种疫苗预防 COVID-19 的免疫机制。
Nat Rev Immunol. 2021 Aug;21(8):475-484. doi: 10.1038/s41577-021-00578-z. Epub 2021 Jul 1.
8
A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model.一种通过新型灭活方法生产的用于 COVID-19 的全病毒疫苗及其在动物攻毒模型中的初步疗效证明。
Vaccines (Basel). 2021 Apr 1;9(4):340. doi: 10.3390/vaccines9040340.
9
A guide to vaccinology: from basic principles to new developments.疫苗学指南:从基本原则到新进展。
Nat Rev Immunol. 2021 Feb;21(2):83-100. doi: 10.1038/s41577-020-00479-7. Epub 2020 Dec 22.
10
Non-Tuberculous Mycobacteria Interference with BCG-Current Controversies and Future Directions.非结核分枝杆菌对卡介苗的干扰——当前争议与未来方向
Vaccines (Basel). 2020 Nov 16;8(4):688. doi: 10.3390/vaccines8040688.